GW Pharmaceuticals' plant-derived CBD drug Epidyolex received approval from Australia's Therapeutic Goods Administration (TGA) to be used in treating seizures related to Lennox-Gastaut syndrome and Dravet syndrome for patients 2 and older.
GW Pharmaceuticals CBD drug gets regulatory OK in Australia is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
From GW Pharmaceuticals CBD drug gets regulatory OK in Australia on CBD Products & CBD Business News – Hemp Industry Daily.
This was autoposted by IFTTT. To find out more, read my post about news articles.
No comments:
Post a Comment